Download as PDF 

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 4, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the appointment of Oppenheimer & Co. Inc. to serve as its strategic advisor. In this capacity, the firm will work on behalf of DelMar to manage the exploration and evaluation of a wide range of strategic opportunities with the goal of facilitating shareholder value generation.

Continue reading DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor →

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Napoleone Ferrara, M.D., to its Board of Directors. Dr. Ferrara is a world-renowned molecular biologist in the field of angiogenesis.

Continue reading DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors →

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., June 26, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today updated patient enrollment data for its Phase 2 open-label clinical trial of VAL-083 in bevacizumab (Avastin®)-naïve recurrent glioblastoma multiforme (rGBM) patients with MGMT-unmethylated status.

Continue reading DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM →

Download as PDF 

Related Documents

MP3 Conference Call Audio PDF HTML 10-K Filing ZIP XLS HTML XBRL

– Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time –

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 24, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on September 25, 2018 at 4:30 p.m. Eastern Time.

Continue reading DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results →